<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00976092</url>
  </required_header>
  <id_info>
    <org_study_id>GE IDE I01209</org_study_id>
    <nct_id>NCT00976092</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Combined Prasugrel and Bivalirudin Versus Clopidogrel and Heparin in Myocardial Infarction</brief_title>
  <acronym>BRAVE-4</acronym>
  <official_title>Randomized Trial of Prasugrel Plus Bivalirudin vs. Clopidogrel Plus Heparin in Patients With Acute STEMI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deutsches Herzzentrum Muenchen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Deutsches Herzzentrum Muenchen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized comparison of two different anticoagulation strategies: prasugrel plus bivalirudin
      versus clopidogrel plus heparin in patients with acute myocardial infarction undergoing
      emergency catheterization and coronary intervention.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary percutaneous coronary intervention (PPCI) is the preferred reperfusion strategy for
      patients with acute ST-segment elevation myocardial infarction (STEMI). Additional
      anticoagulation therapy prior or during intervention plays an important role in the short-
      and long-term outcomes after PPCI. Two separate studies have shown significant benefit
      against conventional therapy based on clopidogrel and heparin for two recently approved
      drugs: the direct thrombin inhibitor bivalirudin and the thienopyridine prasugrel. In the
      HORIZONS-AMI trial, bivalirudin after pretreatment with clopidogrel resulted in improved net
      clinical outcomes. However, during the first 24 hours after PPCI an increase in the stent
      thrombosis rate was observed with bivalirudin therapy. Prasugrel has been shown to be
      superior to clopidogrel in patients with acute coronary syndromes undergoing PCI. The benefit
      in reduction of ischemic complication was even greater in the subset of patients with STEMI
      without any increase in the bleeding risk and with a significant reduction in the stent
      thrombosis rate. Expectedly, the synergic actions of prasugrel and bivalirudin may maximize
      the benefit of antithrombotic therapy for STEMI patients undergoing PPCI.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2009</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>composite of all-cause death, recurrent MI, unplanned IRA revascularization, stroke, definite stent thrombosis or major bleeding</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>all-cause death, recurrent MI, unplanned IRA-revascularization, stroke or definite stent thrombosis</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>major bleeding complications</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiac death</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">548</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Prasugrel + Bivalirudin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 mg prasugrel plus bivalirudin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel + Heparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>clopidogrel as loading and heparin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasugrel</intervention_name>
    <description>60 mg prasugrel as loading dose prior to PPCI</description>
    <arm_group_label>Prasugrel + Bivalirudin</arm_group_label>
    <other_name>Efient</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bivalirudin</intervention_name>
    <description>IV bolus 0.75 mg/kg of body weight followed by an infusion of 1.75 mg/kg/hour during the PPCI</description>
    <arm_group_label>Prasugrel + Bivalirudin</arm_group_label>
    <other_name>Angiox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>600 mg clopidogrel as loading dose before PPCI</description>
    <arm_group_label>Clopidogrel + Heparin</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heparin</intervention_name>
    <description>i.v. bolus of 70-100 IU/kg body weight</description>
    <arm_group_label>Clopidogrel + Heparin</arm_group_label>
    <other_name>unfractionated Heparin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients presenting within 24 hours from the onset of symptoms with STEMI

          2. Informed, written consent

          3. In women with childbearing potential a pregnancy test is obligatory.

        Exclusion Criteria:

          1. Age &lt; 18 years

          2. Cardiogenic shock

          3. Active bleeding; bleeding diathesis; coagulopathy

          4. History of gastrointestinal or genitourinary bleeding &lt;2 months

          5. Refusal to receive blood transfusion

          6. Major surgery in the last 6 weeks

          7. History of intracranial bleeding or structural abnormalities

          8. Suspected aortic dissection

          9. Heparin-induced thrombocytopenia

         10. Any previous stroke

         11. Prior administration of thrombolytics, bivalirudin, low-molecular weight heparin or
             fondaparinux for the index MI

         12. Known relevant hematological deviations: Hb &lt;100g/l, Thromb. &lt;100x10^9/l

         13. Use of coumadin derivatives within the last 7 days

         14. Chronic therapy with nonsteroidal anti-inflammatory drugs (except aspirin), COX-2
             inhibitors, prasugrel

         15. Known malignancies or other comorbid conditions with life expectancy &lt;1 year

         16. Known severe liver disease, severe renal failure

         17. Known allergy to the study medications

         18. Previous enrollment in this trial

         19. Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julinda Mehilli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Deutsches Herzzentrum Muenchen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adnan Kastrati, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Deutsches Herzzentrum Muenchen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Muenchen</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar, Technische Universitaet Muenchen</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81674</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum der Segeberger Kliniken</name>
      <address>
        <city>Bad Segeberg</city>
        <zip>23795</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2009</study_first_submitted>
  <study_first_submitted_qc>September 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2009</study_first_posted>
  <last_update_submitted>January 6, 2014</last_update_submitted>
  <last_update_submitted_qc>January 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>myocardial infarction</keyword>
  <keyword>clopidogrel</keyword>
  <keyword>prasugrel</keyword>
  <keyword>bivalirudin</keyword>
  <keyword>primary PCI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Hirudins</mesh_term>
    <mesh_term>Bivalirudin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

